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Crystal structure and substrate-induced activation
of ADAMTS13
Anastasis Petri1,4, Hyo Jung Kim 2,4, Yaoxian Xu1,4, Rens de Groot 1, Chan Li2, Aline Vandenbulcke3,
Karen Vanhoorelbeke3, Jonas Emsley2,5 & James T.B. Crawley 1,5
Platelet recruitment to sites of blood vessel damage is highly dependent upon von Willebrand
factor (VWF). VWF platelet-tethering function is proteolytically regulated by the metallo-
protease ADAMTS13. Proteolysis depends upon shear-induced conformational changes in
VWF that reveal the A2 domain cleavage site. Multiple ADAMTS13 exosite interactions are
involved in recognition of the unfolded A2 domain. Here we report through kinetic analyses
that, in binding VWF, the ADAMTS13 cysteine-rich and spacer domain exosites bring enzyme
and substrate into proximity. Thereafter, binding of the ADAMTS13 disintegrin-like domain
exosite to VWF allosterically activates the adjacent metalloprotease domain to facilitate
proteolysis. The crystal structure of the ADAMTS13 metalloprotease to spacer domains
reveals that the metalloprotease domain exhibits a latent conformation in which the active-
site cleft is occluded supporting the requirement for an allosteric change to enable accom-
modation of the substrate. Our data demonstrate that VWF functions as both the activating
cofactor and substrate for ADAMTS13.
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Von Willebrand factor (VWF) (Fig. 1a) is critical for pla-telet recruitment at sites of blood vessel damage1. VWFexists as disulﬁde-linked multimers ranging from dimers
to ~100-mers that are released by endothelial cells and platelets
into the plasma2. In circulation, plasma VWF adopts a con-
formation in which the binding sites for platelet GPIbα in the
VWF A1 domain are concealed, allowing VWF to circulate
without unwanted platelet binding3. Following vessel damage,
however, subendothelial collagen is exposed to which globular
VWF binds via its A3 domain. Tethered VWF then undergoes a
structural transition in response to the shear forces exerted by the
ﬂowing blood that exposes the previously hidden GPIbα-binding
sites in its A1 domains3. This facilitates capture of platelets from
blood under high shear leading to formation of the platelet plug.
Larger VWF multimers are more hemostatically competent as
they contain more collagen and platelet-binding sites, and also
more readily unravel under elevated shear forces. High VWF
plasma concentration and large VWF multimer size are risk
factors for thrombosis4–6. Consequently, VWF multimeric size/
platelet-tethering function is proteolytically regulated by the
metalloprotease (MP) ADAMTS135. ADAMTS13 is a ~190 kDa
multidomain plasma glycoprotein. Low ADAMTS13 is associated
with increased risk of myocardial infarction and stroke4. Severe
ADAMTS13 deﬁciency is a hallmark of thrombotic thrombocy-
topenic purpura4. Nascent ADAMTS13 has a short propeptide
that is proteolytically removed prior to secretion5,7. The N-
terminal domains of secreted ADAMTS13 comprise the MP,
disintegrin-like (Dis), a thrombospondin type 1 (TSP1) repeat,
cysteine-rich (Cys-rich), and Spacer domains5. The crystal
structure of the ADAMTS13 DTCS domains has been resolved
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Fig. 1 Von Willebrand factor (VWF) and its exosite interactions with ADAMTS13. a Schematic representation of the domain organization of a VWF
monomer. Locations of disulﬁde bonds involved in VWF multimerization are marked (S–S). Locations of the major ligand-binding sites are shown. b Model
of the central VWF A domains (A1–A2–A3) is shown following shear-induced unfolding. The Tyr1605-Met1606 scissile bond in the VWF A2 domain that is
revealed and cleaved by ADAMTS13 is shown in red. c Amino acid sequence of the entire A2 domain (residues Arg1492-Cys1670). Amino acids previously
suggested to be involved in recognition by different ADAMTS13 domains are highlighted (metalloprotease (MP) domain—red, disintegrin-like (Dis)
domain—yellow, cysteine-rich domain (Cys)—blue, Spacer domain—pink). d VWF A2 domain fragments that were used in this study. VWF96 is a 96
amino acid A2 domain fragment (Gly1573-Arg1668) with a 13 kDa N-terminal SUMO tag and a short C-terminal HSV tag and that spans the ADAMTS13
cleavage site and each of the Dis, Cys-rich, and Spacer domain exosite-binding regions. With the tags, VWF96 has a MW of ~32 kDa. The regions deleted
or mutated in each of the VWF fragments are highlighted. e Schematic representation of the domain organization of ADAMTS13. Domains are labelled. The
C-terminal tail consisting of the thrombospondin (TSP1) repeats 2–8 and CUB domains is depicted folding back to interact with the central Spacer domain.
f The proteolysis of VWF96 (32 kDa) by ADAMTS13 is compared to a previous VWF A2 domain fragment (Glu1554-Arg1668), VWF115 (18 kDa) that lacks
SUMO and HSV tags, but contains a short N-terminal Xpress epitope and 6xHis tag. For this 0.5 nM ADAMTS13 was incubated with 3 μM VWF substrate
at 37 °C. Sub-samples were taken at speciﬁed times and analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) to visualize
proteolysis—note the smallest VWF115 cleavage product is not stained due to its small size. Original gel images are provided in the Source Data ﬁle. These
data reveal that the identity of the tags does not inﬂuence proteolysis
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(i.e., without the catalytic MP domain)8. The C-terminal domains
consist of seven further TSP1 repeats and two CUB domains that
fold back and interact with the central Spacer domain9–12.
There are multiple conformation-dependent exosite interac-
tions between ADAMTS13 and VWF that determine the speci-
ﬁcity and timing of proteolysis13. VWF circulates in a globular
conformation and its central A2 domain is folded such that the
cleavage site is buried, making it resistant to ADAMTS13 pro-
teolysis14. Only when elevated rheological shear forces induce
VWF unravelling (either (i) at sites of vessel damage, (ii) during
endothelial secretion, or (iii) during passage through high shear
environments) are cryptic exosite-binding sites as well as the
Tyr1605-Met1606 cleavage site revealed in the VWF A2 domain
(Fig. 1b, c)13. Speciﬁc recognition of the unfolded A2 domain is
mediated by exosites within the ADAMTS13 Spacer, Cys-rich and
Dis domains that are predicted to sequentially interact with
amino acids Glu1660-Arg1668, Ile1642-Ile1651, and Asp1614-Asp1622
in VWF, respectively (Fig. 1d, e)15–24. These three exosite inter-
actions culminate in the presentation of the scissile bond to the
MP domain active-site13. The multiple exosite interactions have
given rise to the so-called “molecular zipper” model of
ADAMTS13 function13. The ADAMTS13 MP domain contains a
highly conserved 3xHis Zn2+-binding motif and a catalytic
Glu225 residue that form the active-site. Predicted subsites (S1
and S1′ pockets) on either side of the active-site speciﬁcally
accommodate the VWF P1 (Tyr1605) and P1′ (Met1606) resi-
dues21. The ADAMTS13 MP domain also binds the highly
important P3 residue (Leu1603) in VWF25. The MP domain
is predicted to contain a functionally important Ca2+-binding
site adjacent to the active-site, and also an additional double
Ca2+-binding site26.
The mode of action of ADAMTS13 is unusual inasmuch as
proteolysis is dictated by shear-dependent conformational chan-
ges in the substrate (VWF), as opposed to on-demand activation
of the enzyme13. Classically, plasma protease zymogens (e.g.,
complement, hemostatic, ﬁbrinolytic proteases) are proteolyti-
cally activated upon demand. These enzymes frequently rely upon
cofactors to localize or enhance their proteolytic function.
Moreover, inhibition of the proteases within each of these enzyme
systems, through the actions of the large number of plasma
inhibitors, temporally and spatially regulates their function. At
face value, ADAMTS13 does not adhere to this mode of action as
it: (i) is secreted in a seemingly constitutively active form7, (ii)
lacks an “on-demand” activation step, and (iii) has no cofactor
that regulates its function. Despite its apparent constitutive
activity, ADAMTS13 exhibits proteolytic speciﬁcity for a single
site of only one physiological substrate (VWF Tyr1605-Met1606)5.
ADAMTS13 is seemingly resistant to the effects of all plasma
inhibitors and, consequently, it has a very long active plasma half-
life (3–7 days) for a protease, which is, therefore, dictated by
clearance (rather than inhibition)27. To rationalize how
ADAMTS13 exhibits such high substrate speciﬁcity despite cir-
culating as an apparently active enzyme, we hypothesized that
ADAMTS13 circulates in a latent form that requires allosteric
activation mediated by one or more of its exosite interactions
with VWF. Using kinetic analysis of substrate proteolysis, we
demonstrate that, in binding VWF, the ADAMTS13 Cys-rich and
Spacer domain exosites bring the enzyme and the unfolded VWF
A2 domain into proximity. Thereafter, engagement of the
ADAMTS13 Dis exosite with VWF allosterically activates the
MP domain to facilitate proteolysis. Resolution of the crystal
structure of the ADAMTS13 MP to Spacer domains, the ﬁrst such
structure for any ADAMTS family member, reveals that the
active-site cleft in the MP domain is occluded, suggesting a latent
conformation that requires an allosteric change to enable
accommodation of the substrate. Our data thus demonstrate that
VWF functions as an activating cofactor for ADAMTS13 that
precedes its proteolysis.
Results
ADAMTS13 exosites in VWF proteolysis. Physiologically,
ADAMTS13 only proteolyzes the VWF A2 domain once it is
unravelled by elevated shear forces. Recognition of the unfolded
A2 domain occurs through the ADAMTS13 N-terminal domains
(MP through to Spacer—termed MDTCS) (Fig. 1e). Although the
VWF amino acids involved in ADAMTS13 recognition and
proteolysis have been mapped18–20,24,25,28, the biochemical con-
tribution of each exosite interaction to proteolysis has not been
characterized. To do this, we generated a 96 amino acid VWF A2
domain fragment (residues Gly1573-Arg1668, termed VWF96) that
spans the cleavage site and contains all of the MDTCS exosite-
binding regions fused to an N-terminal SUMO tag and a C-
terminal HSV tag. Proteolysis of VWF96 by ADAMTS13 occurs
in the absence of shear-induced unfolding, like previously char-
acterized ADAMTS13 substrates (Fig. 1f)29. We also created
VWF96 variants containing mutations or deletions that speciﬁ-
cally disrupt the Spacer, Cys-rich, or Dis domain exosite inter-
action sites (Fig. 1d). Although not strictly an exosite interaction,
we also substituted the P3 residue (L1603N) in VWF96, which is
important for recognition by the MP domain S3 subsite, to
evaluate the contribution of MP domain recognition beyond the
cleavage site residues. VWF96 fragments were puriﬁed prior to
qualitative analysis of their proteolysis by ADAMTS13 (Supple-
mentary Fig 1). As expected, all VWF96 variants (VWF87
(ΔSpacer), VWF96-Spacer, VWF96-Cys, VWF96-Dis, and
VWF96-MP) were proteolyzed slower than the wild-
type VWF96.
VWF96 proteolysis was monitored kinetically by enzyme-
linked immunosorbent assay (ELISA) to quantify the deﬁciency
associated with disruption of each exosite interaction. From time-
course reactions, we derived the catalytic efﬁciency (kcat/Km) of
proteolysis: 110.7 × 104 M−1 s−1 (Fig. 2a and Table 1), which is
very close to previous estimates for other similar VWF A2
domain fragments20,24,25. Reactions containing the VWF96
variants (using higher ADAMTS13 concentrations to accommo-
date their reduced rates of proteolysis) were analyzed in the same
way. Deletion of the residues associated with the Spacer domain
exosite interaction (Glu1660-Arg1668) in VWF87(ΔSpacer)
resulted in a 14.7-fold reduction in proteolysis (kcat/Km; 7.51 ×
104M−1 s−1) (Fig. 2b and Table 1). Similarly, substitution of
three hydrophobic residues within this same region (L1664T/
V1665N/L1666Q) using VWF96-Spacer caused an 8.4-fold
reduction in proteolysis, demonstrating the contribution of these
hydrophobic amino acids to the Spacer domain exosite interac-
tion (Fig. 2c and Table 1). Disruption of the Cys-rich domain
exosite-binding region in VWF96-Cys (I1642Q/W1644Y/
A1647S/I1649Q/L1650Q/I1651Q) caused a 15.6-fold reduction
in proteolysis, similar to a previous report (Fig. 2d and Table 1)24.
Mutation of the P3 amino acid (L1603N) in VWF96-MP known
to be important for MP domain recognition resulted in 138-fold
reduced proteolysis (Fig. 2f and Table 1)25. The most profound
reduction in catalytic efﬁciency was observed when the Dis
domain exosite-binding region (D1614A/I1616Q/K1617E/
R1618E/D1622T) was mutated (kcat/Km; 0.21 × 104M−1 s−1),
which caused a 527-fold decrease in proteolysis (Fig. 2e and
Table 1).
Kinetic analysis of ADAMTS13 exosite functions. Reductions in
catalytic efﬁciency (kcat/Km) can be caused by increases in Km
(i.e., reduced substrate binding), decreases in kcat, reﬂecting
reduced substrate turnover (indicative of reduced functionality of
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the active-site), or a combination of both. To determine how each
exosite interaction inﬂuences VWF proteolysis, we derived the
individual constants, kcat and Km, through analysis of the initial
rate of proteolysis measured as a function of substrate con-
centration (Fig. 2g–l)20,21,29. For VWF96, we derived a kcat of
5.65 s−1 and a Km of 3.99 μM, which are in close agreement with
previous estimates (Fig. 2g and Table 1)20,21. The independently
derived kcat/Km (141.6 × 104 M−1 s−1) from these data is in
agreement with that from the time-course kinetics (110.7 ×
104 M−1 s−1).
The reduced proteolysis of VWF87(ΔSpacer) and VWF96-
Spacer by ADAMTS13 was associated with increases in Km
(46.1 μM and 32.7 μM, respectively), with little effect upon
the kcat, indicating that the Spacer domain exosite is involved
primarily in substrate binding (Fig. 2h, i and Table 1). Similarly,
the reduction in proteolysis of VWF96-Cys was also due to
reduced substrate recognition (i.e., 30-fold increased Km, 123 μM)
(Fig. 2j and Table 1). Consistent with the proximity of the P3
L1603N mutation to the Tyr1605-Met1606 cleavage site, the 218-
fold reduced proteolysis of VWF96-MP was primarily mediated
by a 66-fold reduction in kcat (0.086 s−1) (Fig. 2l and Table 1),
suggesting that this substitution inﬂuences the accommodation of
the adjacent cleavage site by the MP domain. Disruption of the
Dis domain exosite interaction resulted in a 787-fold reduction in
catalytic efﬁciency (kcat/Km; 0.18 × 104M−1 s−1), similar to that
obtained from the time-course kinetics (0.21 × 104M−1 s−1). This
reduction was due to both a 14-fold increase in Km (56.4 μM),
reﬂecting a role in substrate binding, and a 56-fold decrease in
kcat (0.1 s−1) (Fig. 2k and Table 1). The relative effects of each
exosite interaction are best appreciated when all data are plotted
on the same axes (Supplementary Fig. 2).
The changes in both kcat and Km associated with disruption of
the Dis exosite interaction are indicative of an interaction site that
alters the function of the active-site. This may reﬂect a
mechanism in which the engagement of the ADAMTS13 Dis
domain exosite with VWF allosterically modulates the function-
ality of the active-site in the adjacent MP domain.
ADAMTS13 exosites in VWF A2 domain binding. To corro-
borate the decreases in substrate binding reﬂected by the
increases in Km for VWF96 variant proteolysis, we performed
binding assays using ADAMTS13 (Fig. 3a). As previously
reported, the KD(App) derived for ADAMTS13 binding to an
immobilized A2 domain fragment from these binding assays
Fig. 2 Kinetics of Von Willebrand factor 96 (VWF96) variant proteolysis by
ADAMTS13. a–f VWF96 variants (as labelled) were incubated with
ADAMTS13 (concentration is given for each substrate). Sub-samples at
different time-points (0–2 h) were stopped with EDTA and proteolysis
quantiﬁed by enzyme-linked immunosorbent assay (ELISA). a For VWF96,
0.75 nM ADAMTS13 was used and 750 nM VWF96. Data plotted are
mean ± SD (n= 16). b–f ADAMTS13 concentrations were increased as
noted to accommodate the reduced rate of proteolysis of each VWF96
variant to enable reactions to proceed to completion within 2 h. For all
reactions, the substrate concentration used was <Km for proteolysis. Data
presented are mean ± SD, a n= 16, b n= 4, c n= 3, d n= 7, e n= 8, and
f n= 4. From these time-course reactions, the catalytic efﬁciency (kcat/Km)
for each substrate was derived—see Table 1. g–l ADAMTS13 and VWF96
or VWF96 variants (as labelled) were incubated at 37 °C and proteolysis
monitored over time by ELISA. From each progress curve, the initial rate of
substrate proteolysis ADAMTS13 nM−1 was determined and plotted as a
function of substrate concentration. Data were ﬁtted to derive the Vmax
from which the kcat was derived, and also the Km (concentration of
substrate at Vmax/2). From these data, an independent determination of the
catalytic efﬁciency (kcat/Km) for each substrate was derived—see Table 1.
Note the different axis scales used for VWF96(Dis) and VWF96(MP) due
to the markedly reduced kcat for proteolysis of these two substrates.
Number of different substrate concentrations analyzed were, g n= 113,
h n= 58, i n= 41, j n= 41, k n= 84, and l n= 28. Raw data underlying all
reported averages are provided in the Source Data ﬁle
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(40 ± 1.3 nM) is approximately two orders of magnitude lower
than the Km for proteolysis (4 μM)20,21,29. This likely reﬂects
changes in the conformation of VWF96 when it is adsorbed onto
the plate surface, making it more uniformly permissive to binding
ADAMTS13. In solution, the VWF96 fragment may be in equi-
librium between open and closed states, with only a small pro-
portion (perhaps 1–10%) of VWF96 at any one time being
permissive for higher afﬁnity binding, resulting in the discrepancy
between the Km and KD(App) values. Despite these differences, the
dependency upon the exosites in the N-terminal domains of
ADAMTS13 for both substrate binding and proteolysis is very
similar. Deletion of the Spacer domain exosite-binding region
caused a 12-fold increase in KD(App) (475 ± 61 nM) (Fig. 3a). For
VWF96-Cys there was a 16-fold increase in KD(App) (632 ± 41
nM), similar to the 15-fold increases in KD(App) for VWF96-Dis
binding (615 ± 52 nM). Mutation of L1603 in VWF96-MP
resulted in limited effects upon KD(App).
To analyze solution-phase binding between ADAMTS13 and
the VWF A2 domain fragment, we employed isothermal titration
calorimetry using inactive ADAMTS13 MDTCS(E225Q) and tag-
free VWF73 (Fig. 1). From the isotherms, we derived a solution-
phase KD of 450 nM, which is closer to the Km for proteolysis
than the KD(App) derived from the plate-binding assays (Fig. 3b).
The isothermal proﬁle for the binding of VWF73 to MDTCS
(E225Q) revealed a favorable enthalpic component, but unfavor-
able entropic contribution (Fig. 3c).
Crystal structure of 3H9 Fab-MDTCS complex. Recombinant-
inactive MDTCS was expressed in insect (S2) cells; however,
crystallization with this sample was not successful. As the crystal
structure of the ADAMTS13 DTCS fragment lacking the MP
domain had previously been resolved8, we hypothesized that
MDTCS did not crystallize due to ﬂexibility of the MP domain.
We therefore utilized the Fab fragment of an inhibitory anti-
ADAMTS13 MP domain monoclonal antibody (3H9) to restrict
MP domain ﬂexibility30. We isolated the 110 kDa 3H9 Fab-
MDTCS complex and crystallized this with the structure deter-
mined to a resolution of 2.8 Å (Supplementary Table 1). The
overall structure of 3H9 Fab-MDTCS complex viewed from the
VWF-binding face is illustrated in Fig. 4a. The 3H9 Fab interacts
exclusively with the MP domain—predominantly via interactions
of the Fab heavy-chain CDR1 (residues 24–33), CDR2 (residues
52–57), and CDR3 (residues 99–118) loops engaging the MP
domain at sites that likely overlap with the S1 and S3 selectivity
pockets (Supplementary Fig. 3).
The overall structure of the ADAMTS13 MP domain is
stabilized by multiple disulﬁde bonds and bound Zn2+ and Ca2+
ions, making it unlikely that the inhibitory Fab binding alters the
local main chain conformation signiﬁcantly. Moreover, the
conformation of the ADAMTS13 MP when compared to other
ADAMTS family MP domains (discussed below) reveals that
there are no major differences in the overall structure; however, it
is possible that Fab binding induces subtle changes in the
positioning of the ﬂexible loops or local changes in the side chain
rotamers.
Structure of ADAMTS13 MDTCS. The “front view” of MDTCS
(without the 3H9 Fab) is presented with the active-site and the
functional exosites highlighted (Fig. 4b). In this orientation, the
active-site and each of the Dis, Cys-rich, and Spacer domain
exosites align on the same face of the molecule. Observed from
the “top” (Fig. 4c), MDTCS is “butterﬂy shaped” with the MP and
Spacer domains forming two “outer wings” separated by ~40 Å.
The Dis and Cys-rich domains form the two “inner wings”, which
are separated by the ﬁrst TSP1 repeat. We detected N-linkedT
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glycans on all previously identiﬁed sites within MDTCS (Asn142
and Asn146 in the MP domain, Asn552 in the Cys-rich domain,
and Asn579, Asn614, and Asn667 in the Spacer domain)31. In
addition, we also resolved an O-linked glycan on Ser399, but not
on any of the other previously reported sites31. When compared
to the structure of the ADAMTS13 DTCS domains (PDB ID
3GHM [https://doi.org/10.2210/pdb3GHM/pdb])8, the Dis
domain is “twisted” by ~30° and “declined” by ~7 Å relative to
the Cys-rich domain (Fig. 4d and Supplementary Movie 1).
This is due to differences in the conformation of the central
TSP1 domain, which reduces the distance between Dis and Cys-
rich domain exosites by ~6 Å when compared to the DTCS
structure.
As previously observed8, the Dis and Cys-rich domains are
topologically related involving an α-helix, 3–4 irregular loops, and
a pair of antiparallel β-strands (Fig. 5). The Dis domain is shorter
(47 amino acids) than the Cys-rich domain (67 amino acids),
which also contains a 310 α-helix between L2C and L3C loops.
Loops are denoted as L1-3D and L1-4C according to
the morphology. Although the overall topology of the Dis and
Cys-rich domains is alike, loop arrangements and sizes vary and
they do not superpose well (root-mean-square deviation (RMSD)
= 2.54 Å, 52 aligned residues). The previous DTCS structure
revealed an RMSD value of 1.82 Å (54 aligned residues) when the
Dis and Cys-rich domains were superposed8. In common with
the previous DTCS structure, loop L1D (also termed the V-loop8),
which likely forms part of the Dis domain exosite, and three loops
in the Cys-rich domain are poorly deﬁned in the electron density
indicative of a high degree of ﬂexibility in these domains (Fig. 5).
The electrostatic potential at the molecular surface of MDTCS
reveals that the substrate-binding face of the MP-Dis involves a
ring of positively charged residues Arg326, His328, Arg349, Arg370,
Arg372 from the Dis and Arg257 from MP with a depression at the
center formed by hydrophobic residues Leu351 and Pro353 (Fig. 6).
The distance between the active-site Zn2+ ion and Arg349 in the
Dis domain exosite is 26 Å. This is in good agreement with the
26 Å distance between the VWF Tyr1605-Met1606 scissile bond
(that must lie across the active-site) and Asp1614 (that interacts
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b c
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Fig. 3 Binding of ADAMTS13 to Von Willebrand factor (VWF) A2 domain fragments. a Plate binding of ADAMTS13 to VWF96 variants. VWF96, and
variants thereof, were adsorbed onto 96-well microtiter plates and incubated with increasing concentrations of ADAMTS13 (0–600 nM) for 1 h. Wells
were washed and ADAMTS13 binding detected using an anti-ADAMTS13 TSP2–4 polyclonal antibody. Each concentration was assayed in duplicate on
each plate and the data presented are mean ± SEM of three separate experiments. Data were ﬁtted and the KD(App) derived for ADAMTS13 binding to each
VWF96 variant, which are given. b Solution-phase binding between ADAMTS13 MDTCS(E225Q) and VWF73 was measured by isothermal titration
calorimetry (ITC). Twenty-seven micromolar MDTCS(E225Q) active-site mutant in 20mM HEPES (pH 7.5), 150mM NaCl, and 5mM CaCl2 was placed
into both sample and control cells. Repeated 0.4–2 μl injections of either tag-free VWF73 (279 μM) in 20mM HEPES (pH 7.5), 150mM NaCl, containing
5mM CaCl2 (into the sample cell) or 20mM HEPES (pH 7.5), 150mM NaCl, and 5mM CaCl2 alone (control cell) were performed and heat changes
monitored from which changes in Gibbs free energy (ΔG), enthalpy (ΔH), and entropy (ΔS) were derived as a function of VWF73 concentration. The data
presented are the mean ± SEM of four separate experiments. From the plotted data, the solution-phase binding afﬁnity between MDTCS(E225Q) and
VWF73 was derived (KD; 450 nM). An example of the raw data is depicted in the inset. c MDTCS(E225Q) binding to VWF73 is associated with an
unfavorable entropy change. The data presented are the mean ± SEM of four separate experiments. Raw data underlying all reported averages are provided
in the Source Data ﬁle
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3H9 Fab
‘Front’ view
a
b
c
d
‘Top’ view
DTCS
(PDB:3GHM) 57Å
7Å
30°
MP
Dis
Cys
Spacer
Active site
40Å
51Å
40Å
TSP1
Dis exosite
90°
Cys exosite Spacer exosite
MP Dis TSP1 Cys Spacer
Fig. 4 Crystal structure of 3H9 Fab-MDTCS (MP through to Spacer) complex. a Cartoon representation of ADAMTS13 MDTCS domains bound to the
inhibitory 3H9 Fab fragment (teal) (PDB ID: 6QIG). ADAMTS13 domains are labelled and color-coded according to the schematic representation above.
b Surface structure of ADAMTS13 MDTCS domains (with the Fab removed) viewed from the “front”—substrate-binding face. The ADAMTS13 active-site
and exosites are highlighted with residues implicated in the function of each exosite labelled in the insets. Note the linear alignment of the metalloprotease
(MP) domain active-site and disintegrin-like (Dis), cysteine (Cys)-rich, and Spacer domain exosites. c Surface structure of ADAMTS13 MDTCS domains
(with the Fab removed) viewed from the “top”—rotated forward by 90° from b. MDTCS exhibits a butterﬂy conformation with the MP and Spacer domains
forming “wings” separated by 40 Å. The Dis and Cys-rich domain exosites are separated by a distance of 51 Å. d Surface structure of the previously
determined DTCS domains (3GHM [https://doi.org/10.2210/pdb3GHM/pdb]). The notable difference between the two structures (apart from the
presence/absence of the MP domain) is the location of the Dis and Cys-rich domain exosites, which in our structure is twisted by ~30° and declined by ~7
Å, which reduces the distance between Dis and Cys-rich domain exosites by 6 Å—see Supplementary Movie 1
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with Arg349 in the Dis domain20) when this peptide is arranged in
an extended conformation (Fig. 6). Arg326 and His328 contribute
to the overall positive charge of L1D, whereas Asp340 and Asp343
are responsible for a negatively charged patch on the surface of
L2D (that spans the previously termed hypervariable region8).
The VWF A2 sequence that harbors the Dis domain exosite-
binding region, involving Asp1614, Glu1615, Lys1617, Arg1618, and
Asp1622 shows negative and positive residues that may interact
with the complementary charges in L1D and L2D (Fig. 6).
The main interaction between Cys-rich domain and VWF A2 is
hydrophobic in nature involving Gly471-Val474 (Cys-rich) and
Ile1642-Ile1651 (VWF)24. In ADAMTS13, hydrophobic residues
cluster on the surface involving Leu443, Met446, Ala472, Ala473,
Val474, Leu482, Met486, Met509, Leu620, and Leu621 at the interface
between the Cys-rich and Spacer domains. The Spacer domain
consists of nine antiparallel β-strands and is very similar to the
previous structure of this domain8. Two β-sheets are linearly
aligned, composed of 5 and 4 β-strands, respectively. Hydrophobic
residues point towards the cleft between the two sheets, and all
charged residues (except Glu641) are directed towards the solvent
interface. A long loop (Arg660-Asp672) (also containing two very
short helices) harbors several residues of functional signiﬁcance.
Arg659, Arg660, Tyr661, and Tyr665 within this loop were originally
suggested to be important for the interaction with VWF Glu1660-
Arg166822,23. However, more recently, these residues have been
implicated in the interaction of the Spacer domain with the C-
terminal CUB domains that fold back to form a “closed”
conformation of the full-length molecule (Fig. 1e)9,10. It thus seems
likely that the Spacer domain residues that interact with VWF do
not overlap with this region. Furthermore, given our data revealing
the functional importance of the hydrophobic VWF residues
Leu1664, Val1665, and Leu1666 in binding the Spacer domain exosite,
MP Dis
Y, –90°
a
b
c d
Y, –40°
C
X, 90°
L2D
L1D 310-helix
310-helix
Dis domain
residue 338–353
L3D
residue 354–363
residue 316–337
L4c
residue 503–519
L3c
residue 484–502
L2c
residue 471–478
Loop 490–497
Loop 459–465
Loop 454–468
Cys-rich domain
L1c
residue 452–470
Loop
323–330
R349
L350
V474
A473
A472
N
N
C
TSP1 Cys Spacer
β-pair
Fig. 5 Comparison of the disintegrin-like (Dis) and cysteine (Cys)-rich domain structures. a Ribbon representation of “front” view of MDTCS (MP through
to Spacer) with domains labelled/colored. b Dis (yellow) and Cys-rich (blue) domains are shown in the same orientation to reveal their structural
homology overlaid on the previous ADAMTS13 DTCS domain structure of these domains. c Dis domain (yellow) overlaid on the previous structure of this
domain (gray) with the loops L1-3D labelled. Dis domain exosite residues Arg349 and Leu350 are shown as sticks and highlighted in red. L1D residues
323–330 were missing in the previous DTCS structure of this domain—dotted line. L1D is connected to L2D (Cys322-Cys347) and a β-strand (Cys332-
Cys366), L2D has additional connection with the α-helix (Cys311-Cys337), and L3D is linked with the other β-strand by Cys360-Cys371. d Ribbon
representation of ADAMTS13 Cys-rich domain (blue) overlaid on previously determined DTCS domain structure (gray). Loops L1-4C are labelled. Cys-rich
domain exosite residues Ala472-Val474 are shown as sticks and highlighted in red. Unlike L1D, L1C and L2C are free of disulﬁde bonds and there is a small α-
helix at the end of L2C. This small 310 helix is linked with the β-strand by a disulﬁde bond (Cys483-Cys522). L3C, connected with the main α-helix by Cys450-
Cys487, starts from the end of small α-helix and extended to L4C. L4C has a link with the β-strand by Cys508-Cys527. Unresolved residues from the DTCS
structure (3GHM [https://doi.org/10.2210/pdb3GHM/pdb]) are denoted by dotted lines
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we propose that these residues may form a hydrophobic interaction
with a hydrophobic pocket centered around Ile611 on the substrate-
binding face of the Spacer domain (Fig. 6).
Structure of the ADAMTS13 MP domain. The ADAMTS13
MP domain contains the HEXXHXXGXXH MP motif and a
conserved Met-turn (Met249), which are hallmarks of this
family of proteases32. The Zn2+ ion is coordinated directly by
the side chains of His224, His228, and His234, adjacent to the
active-site Glu225, which is substituted to Gln in our inactive
variant (Fig. 7a, b). Three bound Ca2+ ions are resolved in
the MP domain. The ﬁrst Ca2+ ion (Ca1) is coordinated by the
negatively charged side chains of Asp182 and Glu212 and the
carbonyl backbone of Leu183, Arg190, and Val192. This func-
tionally important Ca2+-binding site is located adjacent to the
active-site cleft and plays a structural role in maintaining the
shape of the active center (Fig. 7b)26. Previously, Asp187 had
been implicated in the coordination of this Ca2+ ion, but our
structure reveals that this amino acid protrudes at the outer
edge of the Ca2+-binding loop and likely fulﬁlls a different
functional role in proteolysis26. Two additional Ca2+ ions form
a double Ca2+-binding site on the rear side of the MP domain
relative to the active-site. Asp166, Asp173, Asp284, and Glu83
coordinate these two Ca2+ ions (Ca2 and Ca3) (Fig. 7b). MP
domain residues 276–305 form a 30 amino acid irregular loop
that connects the Dis domain and is stabilized by connection
with the β5- and β3-strands through the side chain of residue
Asp284 coordinating the Ca2+-binding site (Ca3).
The sequence identity between the ADAMTS13 MP domain
and these other ADAMTS family members is 29% (ADAMTS1),
33% (ADAMTS4), and 29% (ADAMTS5) and superimposition
of the ADAMTS13 MP domain structure with those of
ADAMTS1 (PDB ID: 3Q2G [https://doi.org/10.2210/pdb3Q2G/
pdb]), ADAMTS4 (PDB ID: 4WK7 [https://doi.org/10.2210/
pdb4WK7/pdb]), and ADAMTS5 (PDB ID: 3LJT [https://doi.
org/10.2210/pdb3LJT/pdb]) structures reveals RMSD values of
1.19Å2, 1.10Å2, and 1.10Å2, respectively (Fig. 7c)33–35. In this
comparison, ADAMTS13 is structurally distinct to ADAMTS1, 4,
and 5 in a number of areas; (i) to the right of the Zn2+ ion, three
charged residues Arg193, Asp217, and Asp252 form a triad of
electrostatic interactions with the Arg193 guanidinium at the
center forming two hydrogen bonds to the carbonyl groups of
Ala254 and Asp252, (ii) above the Zn2+ ion there is a hydrophobic
cluster of residues formed by residue Leu147, Leu151, Leu185,
Val192, and Val195 that are located such that they likely form or
shape the S1 pocket that accommodates the P1 residue (Tyr1605)
in VWF (iii) above and below the Zn2+ ion two surface-exposed
acidic residues Asp187 and Glu233 are unique to ADAMTS13,
(iv) the α-helix in the 231–263 loop of ADAMTS1, 4 and 5 is
not formed in ADAMTS13 (Fig. 7c), (v) ADAMTS13 lacks a
disulﬁde bond in the Ca2+-binding loop (Ca1) that is present in
ADAMTS1, 4, and 5 (Fig. 7c).
The most interesting feature of the ADAMTS13 protease
structure is the triad of charged residues formed between Arg193,
Asp217, and Asp252. When metalloproteases accommodate their
substrates, they do so in a standard orientation with the P1
residue in the substrate engaging with the S1 subsite in the MP
domain, positioning the scissile bond over the catalytic center13.
The P1′ residue is also accommodated by the S1′ pocket. In these
proteases, the S1′ pocket is frequently a deep pocket capable of
harboring the R-group of the P1′ residue21. From the crystal
structures of ADAMTS1, 4, and 5 in the presence of active-site
inhibitors, the active-site cleft is open and the S1′ pocket is
revealed (Fig. 8a–c)33–35. In ADAMTS13, the sides of the active-
site cleft are formed by the intimate interactions between loop
180–193 and loop 231–263 mediated by side chains from Arg193,
Asp217, and Asp252. However, the active-site cleft is occluded by
the Ca2+-binding loops 180–193 that folds across the cleft and
blocks the S1′ pocket (Fig. 8d). The S1′ pocket is shaped by
residues Asp252-Pro256 21. Therefore, whereas the Zn2+ ion is
accessible, a triad of salt bridge interactions between the side
chains of Arg193 with both Asp217 (on the α4-helix that runs
along the base of the cleft) and Asp252 (in the loop 231–263)
appear to stabilize the closure of the active-site cleft (Fig. 8e and
Supplementary Movie 2). We propose, therefore, that this
structure represents a latent conformation that is unable to
accommodate a peptide substrate. Arg193, Asp217, and Asp252,
herein termed the “gatekeeper triad,” blocks both the S1′ pocket
and the passage that VWF must take if it is to interact with both
Active
-site
MP
26Å
Y1605 D1614
D1622 VWF(Y1605-D1622)
Dis
TSP1
Cys
Spacer
Hydrophobic
patch
Fig. 6 Electrostatic potential at the molecular surface of ADAMTS13 MDTCS (MP through to Spacer). The charged surface representation of MDTCS is
presented in the “front” view as in Fig. 4 b (negative charges—red; positive charges—blue). Domains are labelled above. The active-site and the disintegrin-
like (Dis), cysteine (Cys)-rich and Spacer domain exosites are circled. The L1D loop in the Dis domain that was not fully resolved in the DTCS structure is
highlighted, and also the L2D loop. Together, these loops provide the interaction site for reciprocally charged Von Willebrand factor (VWF) residues
1615–1622. The peptide Tyr1605-Asp1622 is shown. The distance from the metalloprotease (MP) domain active-site to Arg349 in the Dis domain is 26 Å,
which matches the distance from the Tyr1605-Met1606 scissile bond to Asp1614 that interacts with Arg349. The Spacer domain exosite involving Arg660,
Tyr661, and Tyr665 has been reported to interact with the C-terminal CUB domains of ADAMTS13. We propose that the Spacer domain makes a
hydrophobic interaction with Leu1664, Val1665, and Leu1666 with an adjacent surface hydrophobic patch (green) centered around Ile611
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the Dis domain exosite (located at the end of the active-site cleft)
and the active-site itself (Supplementary Movie 2). Arg193,
Asp217, and Asp252 are unique to ADAMTS13 (Fig. 7d), but
are conserved across an amino acid sequence alignment of species
from the human to zebraﬁsh ADAMTS13.
Discussion
Of the 19 ADAMTS family members, ADAMTS13 is the only
member with a known role in blood plasma. The importance of
its physiological role is highlighted by the severe thrombotic
phenotype associated with its inherited or acquired deﬁciency5.
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Where known, the other family members function primarily in a
tissue milieu with substrate targets broadly associated with matrix
and cartilage homeostasis36. The proteolytic targets of many of
the ADAMTS family proteases remains undeﬁned, although a
common theme is their speciﬁcity for large, often multimeric,
structural glycoproteins. All ADAMTS family members contain
the MDTCS domains, but differ in the number and identity of C-
terminal domains. The conservation of the MDTCS region points
to a common mode of action for these domains. Our functional
studies reveal that ADAMTS13 contains exosites in each of its
Dis, Cys-rich, and Spacer domains that all contribute to the
molecular zipper model of substrate recognition and proteolysis.
Whereas the presence of these exosites has been known for some
time15,17–25, their relative importance and biochemical con-
tributions to proteolysis had not been elucidated. Our kinetic data
reveal that the Cys-rich and Spacer domain exosites are primarily
involved with substrate recognition/binding due to the large
increases in both the Km and KD associated with disruption of
their binding sites in VWF96. The Dis domain also harbors a
VWF-binding site primarily involving ionic interactions that,
Fig. 7 Structure and sequence comparison of ADAMTS13 metalloprotease (MP) domain. a Crystal structure of the ADAMTS13 MP domain with the
topology β1-α1-α2-β2-α3-β3-β4-β5-α4-α5. Loop 180–193, loop 231–263, the active-site, and the metal-binding sites are indicated. Two N-linked glycans are
shown in purple. Surface residues Leu147, Leu151, Leu185, Val192, and Val195 (light green) form a hydrophobic patch above the active-site that likely
contributes to the S1 pocket. Asp187 and Glu233 (dark teal) are negatively-charged residues that are unique to ADAMTS13. To the right of the active-site,
Arg193, Asp217, Asp252 and Ala254 (blue) form ionic interactions with each other that bridge loops 180–193 and 231–263. b Four metal ions are bound by
the MP domain: the Zn2+ ion (gray sphere) is coordinated by His224, His228, and His234. Three Ca2+ ions are bound (green spheres); a single Ca2+ ion
(Ca1) bound by loop 180–193 is coordinated by Asp182, Glu212 and the carbonyl backbone of Leu183, Arg190, and Val192. Two Ca2+ ions (Ca2 and Ca3) are
bound in a double Ca2+-binding site on the rear side of the MP domain. c Superimposition of human ADAMTS13 MP domain (salmon) with the structures
of human ADAMTS1 (light blue, 1.19 Å root-mean-square deviation (RMSD), 971 Cα atoms, PDB 3Q2G [https://doi.org/10.2210/pdb3Q2G/pdb]),
ADAMTS4 (gray, 1.10 Å RMSD, 923 Cα atoms, PDB 4WK7 [https://doi.org/10.2210/pdb4WK7/pdb]), and ADAMTS5 (purple, 1.10 Å RMSD, 832 Cα
atoms, PDB 3LJT [https://doi.org/10.2210/pdb3LJT/pdb]). Regions enclosed with black boxes are enlarged in the right panel. Top panels show the Ca2+-
binding loop (loop 180-193). ADAMTS13 Glu184 and Arg190 interact ionically in place of the disulﬁde bonds that are found in ADAMTS1, ADAMTS4, and
ADAMTS5. Bottom panels highlight differences in the loop 231–263. In ADAMTS1, 4 and 5 in there is an α-helix in this loop, whereas in ADAMTS13 this α-
helix is not formed and is presented as the α-helix-less loop. d Sequence alignment of ADAMTS13 MP domain residues 171–263 with other ADAMTS family
members. Identical residues are colored white on a red background and similar residues are red on white background. The Ca2+-binding loop (loop
180–193) is highlighted. “Gatekeeper triad” residues Arg193, Asp217, and Asp252 are denoted by red arrows, which are not present in other ADAMTS family
members
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e
b c d
‘Active’ ADAMTS4 ‘Active’ ADAMTS5
‘Latent’ ADAMTS13
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Dis
Dis
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‘Latent’ ADAMTS13
Fig. 8 The ADAMTS13 metalloprotease (MP) domain exhibits a “closed” conformation and a “gatekeeper triad.” a–c Structures of the active-sites of
ADAMTS1, 4, and 5 resolved in the presence of active-site inhibitors (not shown) revealing the conformation of the “active” protease when the active-site
accommodates a substrate PDB ID: 3Q2G [https://doi.org/10.2210/pdb3Q2G/pdb], 4WK7 [https://doi.org/10.2210/pdb4WK7/pdb], and 3LJT
[https://doi.org/10.2210/pdb3LJT/pdb], respectively. Active-site His residues are shown in red with bound Zn2+ ion shown as a gray sphere—all
structures are shown in the same orientation. In the standard orientation for MP domain substrate engagement, the scissile bond lies over the active-site.
The R-group of the P1 residue is accommodated by the S1 pocket (highlighted). The S1′ pocket is recessed into the MP domain to accommodate the P1′
residue R-group (arrows). d In ADAMTS13, the S1′ pocket is occluded due to ionic interactions of the “gatekeeper triad” (gray) residues giving a “latent”
conformation. e Structure of the ADAMTS13 MP-disintegrin-like (Dis) domains. The active-site and Dis exosite are shown in red, both of which interact
with Von Willebrand factor (VWF). The Ca2+-binding loop above the active-site cleft forms an ionic interaction via Arg193 with both Asp217 and Asp252
(gray). This ionic interaction of the “gatekeeper triad” blocks the active-site cleft and hence the passage between the active-site and the Dis exosite—see
Supplementary Movie 2
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when it engages VWF, enhances the proteolytic function of the
MP domain. This effect was measured through a 56-fold decrease
in the kcat (and 14-fold increase in Km) for VWF96 proteolysis
when the Dis exosite-binding region in VWF96 was disrupted.
For mutations in the substrate to exert such an effect upon the
function of the MP domain strongly supports the contention that
engagement of this exosite with VWF induces a conformational
change to the adjacent MP domain that allosterically enhances its
enzymatic function. This substrate-induced activation of the
enzyme adds a further level of complexity to the molecular zipper
mechanism that describes ADAMTS13 function.
The crystal structure of the MDTCS domains, which is cur-
rently the only one to encompass all of these domains of any of
the 19 ADAMTS family members, revealed that the Ca2+-binding
loop 180–193 in the MP domain occludes the active-site cleft and
a ring of positive charge deﬁnes the substrate-binding interface
spanning the MP and Dis domains. This seemingly latent con-
formation is stabilized by ionic interactions between the “gate-
keeper triad” consisting of Arg193, Asp217, and Asp252 that
sterically hinders accommodation of a peptide bond across the
active-site (Supplementary Movie 2). We propose that this
structure corresponds to the circulating latent form of
ADAMTS13 and provides important insight into the mode of
action for ADAMTS13 (Fig. 9). Normally, VWF circulates in a
globular conformation that cannot bind platelets and is resistant
to ADAMTS13 proteolysis (Fig. 9a). ADAMTS13 also circulates
in a “closed” form mediated by interaction of the CUB domains
with the Spacer domain9,10,37. The MP domain of circulating
ADAMTS13 favors a latent conformation stabilized by the ionic
interactions of the “gatekeeper triad.” This prevents off-target
proteolysis of plasma proteins, and also likely confers resistance
to inhibition by broad-spectrum plasma inhibitors as the active-
site is not permissive to accommodating a peptide sequence. This
would explain how the very long plasma half-life of ADAMTS13
(3.5–8 days) is conferred, which is determined by clearance, as
opposed to inhibition27. When VWF unravels in response to
elevated shear forces (at sites of vessel damage, upon secretion,
etc.), it unfolds to facilitate platelet capture. The VWF A2 domain
also unfolds to expose the ADAMTS13 cleavage site and exosite-
binding regions (Fig. 9b). ADAMTS13 interacts with VWF via
the D4-CK region, which “opens” ADAMTS13 up. This enhances
ADAMTS13 enzyme activity by ~2-fold against short A2 domain
fragment substrates. The Spacer and Cys-rich domains interact
with the unfolded A2 domain (Fig. 9c). The Dis domain exosite
then engages VWF, which transduces an allosteric change in the
MP domain that disrupts the “gatekeeper triad,” removing the
loop 180–193 from the active-site cleft and converting the latent
form into its active conformation (Fig. 9d). This allosteric,
substrate-assisted activation enhances ADAMTS13 proteolytic
activity of the MP domain by allowing accommodation of the
scissile bond into the active-site cleft. ADAMTS13 then
dissociates and can recycle to its “closed” and latent form. In this
scheme, VWF functions as both the activating cofactor and
substrate for ADAMTS13.
The dependence of plasma proteases upon cofactors is a
common theme in hemostasis. Activated factor VII is essentially
proteolytically inactive unless it is allosterically activated by its
cofactor, tissue factor38. Activated factor IX is also inert unless
bound to its cofactor, factor VIIIa, and is further allosterically
activated by binding its substrate, factor X39. Similarly, tissue-
plasminogen activator is allosterically activated by binding to
ﬁbrin40. These hemostatic enzymes are all serine proteases, and,
to the best of our knowledge, this description of ADAMTS family
allostery involving conformational activation of the MP domain
may provide mechanistic insight into other family members.
Previous descriptions referring to ADAMTS13 allosteric
activation have used this term to describe the opening of
ADAMTS13 by dissociation of the CUB domains from the Spacer
domain10–12,37, rather than more classical enzyme allostery
associated with structural shifts in the protease domain. We
propose that the allosteric activation of ADAMTS13 serves to
spatially and temporally localize its proteolytic function and
confer its high substrate speciﬁcity.
ADAMTS family members have a propeptide that can be
removed by furin/furin-like proteases36. These propeptides
contain a Cys-switch motif that interacts with the active-site,
conferring latency until it is removed—either intracellularly or
at the cell surface. This inhibits proteolytic activity and prevents
proteolysis of intracellular proteins prior to secretion. The
ADAMTS13 propeptide is much shorter than those of all other
family members and does not possess a Cys-switch motif, and
consequently does not confer enzyme latency7,41. That
the ADAMTS13 MP domain appears to naturally assume a
latent conformation may be an evolutionary trait that accom-
modates its non-inhbitory propeptide. The “gatekeeper triad”
residues are unique to ADAMTS13 amongst ADAMTS family
members, but are perfectly conserved between species, sug-
gesting that these are functionally/evolutionarily important
residues (Fig. 7d). Although the “gatekeeper triad” may be
speciﬁc to ADAMTS13, the adoption of a latent MP domain
fold may not. The crystal structures of the MP domain of
ADAMTS1 and 4 have previously been resolved in both the
absence and presence of small molecule active-site inhibitors
and suggest the need for a structural shift to accommodate their
substrates33,35. Whether substrate-induced enzyme activation is
a common mode of action amongst ADAMTS proteases
remains to be determined. However, given the conservation of
the MDTCS domains between all members, ADAMTS13 may
provide a template for understanding the biochemistry for this
family of metalloproteases.
Methods
Preparation of VWF A2 substrates. The coding region for the 96 amino acid A2
domain fragment—termed VWF96, VWF (Gly1573-Arg1668), fused to an N-
terminal 6xHis-SUMO tag (Invitrogen) and a C-terminal HSV-6xHis in pET25b
(+) (Novagen) was generated and veriﬁed by sequencing. Primer sequences for
ampliﬁcation and cloning into pET-SUMO vector and subsequent subcloning into
pET25b(+) are provided in Supplementary Table 2. The 13-kDa N-terminal
6xHis-SUMO tag (Invitrogen) fuses a derivative of the yeast Smt3 protein, which
aids in protein solubility. The C-terminal HSV-6xHis tag (Novagen) is a short
peptide sequence (SQPELAPEDPEDVEHHHHHH) for which high-afﬁnity anti-
bodies are available. A panel of variants of this vector were generated to ablate each
ADAMTS13 exosite-binding region (Fig. 1). Amino acids that were substituted or
deleted were identiﬁed by previous mutagenesis studies19,20,24,25,28, with the
intention of ablating or severely disrupting each ADAMTS13 exosite binding
interaction. To ablate the Spacer domain exosite interaction, residues Glu1660-
Arg1668 were deleted in VWF87(ΔSpacer). A variant was also made in which three
hydrophobic residues within this region were substituted (L1664T/V1665N/
L1666Q) in VWF96-Spacer. For the Cys-rich domain exosite-binding region,
I1642Q/W1644Y/A1647S/I1649Q/L1650Q/I1651Q mutations were introduced in
VWF96-Cys, as previously reported24. The Dis domain exosite-binding region was
mutated (D1614A/I1616Q/K1617E/R1618E/D1622T) to make VWF96-Dis based
on the study by Kretz et al. 28. For the MP domain-binding region, we substituted
the P3 residue (L1603N) based on the report of Xiang et al.25 to generate VWF96-
MP. We did not substitute the cleavage site, which forms further interactions with
the MP domain. Primers used for the generation of each variant are provided in
Supplementary Table 2.
BL21 (DE3) Escherichia coli (Invitrogen) were transformed with vectors and
single colonies inoculated into LB broth containing 100 μg ml−1 ampicillin. These
were expanded to 2.5 L cultures with shaking at 37 °C. VWF96 variant expression
was induced by the addition of 1 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG), followed by expression for 5 h. Harvested cells were resuspended in
BugBuster® Master Mix (Novagen) containing lysozyme (0.15 mgml−1),
benzonase (25 Uml−1), and containing protease inhibitors (Sigma). The cell
resuspension was incubated at room temperature for 10 min with mixing and
centrifuged at 10,000 × g for 20 min at 4 °C. Pellets were resuspended in
BugBuster® Master Mix, incubated at room temperature for 10 min with shaking,
and centrifuged as before. The supernatants were pooled and cleared through
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0.2 µm ﬁlters. The ﬁltered lysate was applied to a HiTrap® Chelating HP column
(GE Healthcare) bound to Ni2+ and equilibrated with 20 mM Tris-HCl (pH 7.6)
and 0.5 M NaCl. VWF96 and variants thereof were eluted with step wise imidazole
concentrations (30, 60, 100, 150, 200, 250, and 300 mM) in 20 mM Tris-HCl
(pH 8.5) and 0.5 M NaCl. Fractions containing VWF96 were identiﬁed by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), and dialyzed in
20 mM Tris-HCl (pH 8.5), 50 mM NaCl, and applied to a Capto Q ImpRes column
(GE Healthcare). The column was then washed by 20 mM Tris-HCl (pH 7.6),
50 mM NaCl, and VWF96 variants were eluted from the column by NaCl gradient
from 50mM to 2M. Puriﬁed proteins were analyzed by SDS-PAGE and Coomassie
staining, and also by Western blotting using 0.12 μg ml−1 anti-SUMO/SUMOStar
(LifeSensors; AB7002) and 0.2 μg ml−1 anti-HSV (Bethyl; A190-136A) antibodies
(Supplementary Fig. 1). Puriﬁed proteins >95% pure were dialyzed in 20 mM Tris
(pH 7.6), 50 mM NaCl, 5 mM CaCl2 (TBSC), and quantiﬁed by absorbance at
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GPIbα
Fig. 9 Mode of action of ADAMTS13. a Under normal circumstances, multimeric Von Willebrand factor (VWF) circulates in the plasma in a globular
conformation, in which its A1 domains are concealed, and so does not interact with platelets. ADAMTS13 circulates in a “closed” conformation stabilized
through the interaction of the C-terminal CUB domains with the central Spacer domain. The MP domain of ADAMTS13 also has a latent conformation in
which the active-site cleft is occluded by the Ca2+-binding loop. This prevents ADAMTS13 from proteolyzing off-target substrates and confers resistance
to plasma inhibitors. b Following vessel damage, the endothelium (EC) is disrupted to reveal subendothelial collagen. Globular VWF binds to this surface
via its A3 domain and unravels into an elongated conformation in response to the shear forces exerted by the ﬂowing blood. This reveals the A1 domain
that can then capture platelets via the GPIbα receptor on the platelet surface. Unravelling of VWF also unravels the VWF A2 domain into a linear
polypeptide conformation that reveals the binding sites for ADAMTS13 and the Tyr1605-Met1606 cleavage site, making it susceptible to proteolysis by
ADAMTS13. c ADAMTS13 recognizes unfolded VWF through multiple interactions. (1) The CUB domains bind the VWF D4-CK domains, which (2)
induces their dissociation from the Spacer domain. (3) The Spacer and (4) cysteine (Cys)-rich domain exosites recognize the C-terminal region of the
unfolded A2 domain to bring the enzyme and substrate into proximity. d Once bound, (5) the disintegrin-like (Dis) domain exosite engages VWF residues
Asp1614-Asp1622. This interaction (6) induces an allosteric change in the MP domain. This causes a conformational change, disrupting the “gatekeeper
triad” that otherwise occludes the active-site cleft, to reveal the S1′ pocket. Once allosterically activated, (7) the MP domain proteolyzes the scissile bond
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280 nm using the calculated extinction coefﬁcients of each variant. Expression
vectors for VWF96 and its variants and for samples of recombinant proteins are
available upon reasonable request.
ADAMTS13 activity assays. For qualitative analysis of VWF96 proteolysis,
concentrated recombinant ADAMTS13 in conditioned medium and puriﬁed
VWF96 variants in TBSC were preincubated at 37 °C for 15 min. Reactions (ﬁnal
volume 135 μl) were set up using 0–53 nM ADAMTS13 and 3 μM VWF96 variants
in TBSC buffer. Twenty-ﬁve microliters of reaction samples were removed and
stopped every 30 min for 1.5 h by mixing with EDTA. Samples were analyzed by
SDS-PAGE and Coomassie staining.
For kinetic analyses, ADAMTS13 in conditioned medium and puriﬁed VWF96
variants were incubated separately in TBSC/1% bovine serum albumin (BSA) at
37 °C for 15 min, as previously described20,21,23–26. Reactions were set up using
0.75–505 nM ADAMTS13 and VWF96 variants (0.5–300 μM) in TBSC/1% BSA.
Ten microliters of reaction sub-samples were stopped between 0 and 120 min with
EDTA. The stopped sub-samples were diluted to 0.09 nM VWF96 in TBS/1% BSA
buffer and analyzed by VWF96 ELISA to quantify the concentration of uncleaved
substrate.
VWF96 ELISA and kinetics of proteolysis. Polyclonal chicken anti-SUMO/
SUMOstar (0.5 μg ml−1) IgY (LifeSensors; AB7002) was adsorbed onto 96-well
microtiter plates in 50 mM sodium carbonate/bicarbonate (pH 9.6) overnight at
4 °C. Wells were washed with phosphate-buffered saline (PBS)/0.1% Tween and
blocked with TBS/3% BSA for 2 h. Wells were washed, and a standard curve of
puriﬁed VWF96 (0–0.15 nM) diluted in TBS/1% BSA was added. In parallel,
stopped samples were diluted in TBS/1% BSA to a ﬁnal concentration of 0.09 nM
VWF96 and incubated at room temperature for 1.5 h. After washing, 0.5 μg ml−1
peroxidase-conjugated anti-HSV IgG (Bethyl; A190-136P) diluted in TBS/1% BSA
was added and incubated for 1 h. Wells were washed and 170 μl SIGMAFAST™ o-
phenylenediamine dihydrochloride peroxidase substrate (Sigma) was used for the
detection. Color development was stopped using 2.5 M H2SO4 and measured
spectrophotometrically at 492 nm.
The concentration of uncleaved substrate at each time-point was measured
from the standard curve and, from this, the fraction of substrate proteolyzed was
calculated and plotted as a function of time. For each VWF96 variant the number
of reactions performed is provided in the ﬁgure legends. The catalytic efﬁciency,
kcat/Km, was determined using GraphPad software (Prism) by ﬁtting the data from
the time-course reactions into the equation, P= 1− exp(−1 × [ADAMTS13] × t ×
kcat/Km), where P is the fraction of VWF96 proteolyzed and t is the time in seconds.
To obtain the separate kinetic constants, kcat and Km, for VWF96 variant
proteolysis, multiple time-course reactions were performed as described above to
determine the initial rate of substrate proteolysis as a function of VWF96 variant
concentration (0.2–350 μM). The number of reactions/concentrations performed
for each substrate is provided in the ﬁgure legends. All assays were performed on
multiple different preparations of both recombinant substrates and ADAMTS13.
From each time-course analysis, the initial rate of proteolysis (at <15% proteolysis)
was calculated (in nM s−1), normalized per unit (nM) of ADAMTS13 used, and
plotted as a function of substrate concentration. The Michaelis–Menten equation
was used to ﬁt the data using the GraphPad software (Prism), Vi= (Vmax ×
[VWF96])/(Km+ [VWF96]), where, Vi is the initial rate (nM s−1), Vmax is the
maximum velocity, Km is the Michaelis constant, and kcat (s−1) is the catalytic
constant for proteolysis, or turnover number, which measures the functionality of
the active-site of each unit of enzyme (kcat= Vmax/[ADAMTS13]).
Binding assay between ADAMTS13 and VWF96 variants. Binding assays using
immobilized VWF96 were performed essentially as previously described20,21,23–26.
In 96-well microtiter plates, 100 nM VWF96 or VWF96 variants, diluted in 50 mM
sodium bicarbonate buffer (pH 9.6), were adsorbed overnight at 4 °C. Wells were
washed with PBS/0.1% Tween and blocked with 300 μl PBS/3% BSA for 2 h. Wells
were washed, and 100 μl of 0–600 nM ADAMTS13 in PBS/1% BSA/80 mM EDTA
were added and incubated at room temperature for 1.5 h with shaking.
ADAMTS13 was also added to uncoated, blocked wells, to control for non-speciﬁc
binding. A buffer-only sample was also included to remove any background
absorbance. Bound ADAMTS13 was detected using a biotinylated anti-
ADAMTS13 TSP2–4 polyclonal antibody (0.2 μg ml−1), as previously described24.
All conditions were performed in duplicate and the mean for each well derived.
After subtracting any signal from control wells, the data were ﬁtted in the
GraphPad software (Prism) using the one-site binding equation: B= Bmax ×
[ADAMTS13]/(KD(App)+ [ADAMTS13]), where B is the percentage speciﬁc
binding, Bmax is the maximal binding, and KD(App) is the apparent equilibrium
dissociation constant. Data are presented as mean ± SEM of three separate
experiments each performed in duplicate.
Expression and puriﬁcation of MDTCS. The complementary DNA encoding the
canonical human amino acid sequence of the MDTCS domains (Gly78-Pro682) (i.e.,
without the native signal peptide or propeptide) was cloned into the insect cell
expression vector pMT-BiP-PURO. Primers used for ampliﬁcation and cloning are
provided in Supplementary Table 2. This vector fuses the Drosophila BiP secretion
signal to the N terminus of the MP domain to enable entry into the S2 cell
secretory pathway. The BiP signal peptide is cleaved off prior to secretion by the
cells to provide a native N terminus (Gly78). At the C terminus there is a 6xHis tag
fused to facilitate puriﬁcation. The active-site Glu225 was mutated to Gln (E225Q)
by site-directed mutagenesis and veriﬁed by sequencing. Primers used for muta-
genesis are provided in Supplementary Table 2. This vector was transfected into
Drosophila Schneider 2 cells using calcium phosphate, and stably transfected cells
were selected using Schneider’s Drosophila medium (Lonza) containing 10% (v/v)
fetal calf serum and 10 μg ml−1 puromycin (Gibco) for 3–4 weeks. Cells stably
expressing MDTCS(E225Q) were expanded to 1 L in Ex-cell™ 420 serum-free
medium (Sigma)/10 μg ml−1 puromycin in 2.5-L ﬂasks at 27 °C/120 rpm to a cell
density of 2–4 × 106 cells ml−1. To these, copper sulfate (0.5 mM ﬁnal concentra-
tion) was added to induce target protein expression. Cells were cultured for a
further 7 days and media harvested by centrifugation and ﬁltration.
Conditioned media were concentrated by tangential ﬂow ﬁltration using a
10 kDa ﬁltration unit (Millipore) and dialyzed into 20 mM HEPES (pH 7.5), 0.5 M
NaCl, 5 mM CaCl2, and 10 mM imidazole. The dialyzed medium was applied to a
HiTrap® Chelating HP column (GE Healthcare) bound with Ni2+. The column
was washed and MDTCS(E225Q) eluted through step wise increases in imidazole
concentration (30, 60, 100, 150, 200, 250, and 300 mM). Fractions were analyzed by
SDS-PAGE and Coomassie staining and the 100 mM imidazole elution fractions
containing the highest concentrations of MDTCS(E225Q) were dialyzed into
20 mM HEPES (pH 7.5), 150 mM NaCl, and 5 mM CaCl2, and further puriﬁed by
gel ﬁltration using a HiPrep® 26/60 Sephacryl S-200HR column (GE Healthcare).
The elution fractions containing MDTCS(E225Q) with a C-terminal 6xHis tag
were concentrated using Amicon centrifugal ﬁlter (10 kDa cut-off) to 4–7 mg/ml.
For isolation of a stable complex between MDTCS(E225Q) and the 3H9 Fab
fragment, proteins were mixed in a 1:1.2 ratio prior to size exclusion
chromatography. Expression vectors for ADAMTS13 and its variants and for
samples of recombinant proteins are available upon reasonable request.
3H9 Fab generation. Hybridoma cells expressing the inhibitory anti-ADAMTS13
monoclonal antibody, 3H9, were produced in a large scale bio-incubator (Celline
CL 350, Integra Biosciences)30,42. From conditioned media, the 3H9 antibody was
puriﬁed using protein A-coupled Sepharose FF (GE Healthcare). Fab fragments of
3H9 were generated proteolytically using papain and subsequently isolated using
HiTrap® Q HP anion exchange column (GE Healthcare).
Crystallization and structure determination. Crystals of the 3H9 Fab-MDTCS
(E225Q) complex were grown using sitting-drop vapor diffusion at 20 °C. Initial
crystallization conditions were established using screening kits from Hampton
Research (Index) and from Molecular Dimensions (JCGS I, II, III, and IV, MIDAS,
ProPlex, and Structure Screen I and II). For the optimal growth of the 3H9 Fab-
MDTCS(E225Q) crystals, 1 μl (8 mg ml−1) was mixed with 1 μl of precipitant
solution (35% (v/v) pentaerythritol ethoxylate (15/4 EO/OH), 200 mM CaCl2,
100 mM HEPES, pH 6.5) and this was equilibrated against a 1 ml reservoir of the
precipitant solution. Crystals were ﬂash frozen in a stream of nitrogen at 100 K and
diffraction data were collected at the I24 beamline of the Diamond Light Source,
UK. Data were processed and scaled using XDS and the CCP4 suite43,44. The
crystals belonged to space group P3221 and contained one molecule per asym-
metric unit. To determine the structure, molecular replacement was used with the
program Phaser within CCP4 suite using the available templates of the
ADAMTS13 DTCS domains (PDB: 3GHM [https://doi.org/10.2210/pdb3GHM/
pdb]), the MP domain of ADAMTS4 (PDB: 4WK7 [https://doi.org/10.2210/
pdb4WK7/pdb]), and a Fab antibody fragment structure (PDB: 2HRP) as search
models45. Iterative cycles of model building were performed using COOT, followed
by reﬁnement with Refmac5 and phenix46–49. In the electron density loop regions
spanning residues 324–330 (Dis domain) and 450–453, 469–479, 488–489,
498–500 (Cys-rich domain) are poorly deﬁned, suggesting that these regions are
ﬂexible. A portion of the data (5%) was set aside before the reﬁnement calculations
of Rfree. Solvent molecules were added in the later stages of reﬁnement and ﬁnal
crystallographic statistics are summarized in Supplementary Table 1. Structural
alignments and ﬁgures were generated using PyMOL (http://www.pymol.org) and
UCSF chimera50.
Preparation of VWF73. The coding region for the 73 amino acid human VWF A2
domain fragment (Asp1596-Arg1668) was cloned into pET-SUMO (Invitrogen)
containing an N-terminal 6xHis-SUMO tag. This vector was transformed into One
Shot BL21 Star (DE3) E. coli cells (Invitrogen). Cells were cultured in 200 ml LB
media containing kanamycin at 37 °C. One millimolar IPTG was added to induce
6xHis-SUMO-VWF73 protein expression and cultured for 4 h. Cells were har-
vested and VWF73 puriﬁed in the same way as VWF96. Fractions containing pure
6xHis-SUMO-VWF73 were identiﬁed by SDS-PAGE. 6xHis-SUMO-VWF73 was
incubated with His-tagged SUMO protease-1 (LifeSensors) and 2 mM dithio-
threitol at 30 °C for 72 h to remove the His-SUMO tag. Tag-free VWF73 was
separated from the cleaved His-SUMO tag and SUMO protease-1 by application to
a 1 ml HiTrap® Chelating HP column (GE Healthcare) bound to Ni2+. Tag-free
VWF73 was dialyzed in 20 mM HEPES (pH 7.5), 150 mM NaCl, 5 mM CaCl2, and
concentrated using a 3 kDa cut-off centrifugal ﬁlter (Amicon) and quantiﬁed by
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absorbance at 280 nm using the calculated extinction coefﬁcient of tag-
free VWF73.
Isothermal titration calorimetry. ITC was performed using a MicroCal PEAQ
ITC (Malvern Instruments). All buffers/reagents were degassed prior to use. For
this, 280 µl of 27 μM MDTCS(E225Q) in 20 mM HEPES (pH 7.5), 150 mM NaCl,
and 5 mM CaCl2 was injected into the sample cell at 25 °C and buffer only into the
control cell. Repeated 0.4–2 μl injections of 279 μM VWF73 in 20 mM HEPES (pH
7.5), 150 mM NaCl, and 5 mM CaCl2 were applied to both cells every 150 s with
mixing (500 rpm). Thermograms were obtained and ﬁtted via nonlinear least-
squares minimization method to determine the KD and change in enthalpy of
binding (ΔH). The Gibbs free energy of binding, ΔG, was calculated from Ka values
and the entropic term, TΔS, was derived from the Gibbs–Helmholtz equation using
the recorded ΔH values. The data presented are the mean ± SEM of four separate
experiments.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Data supporting the ﬁndings of the study are available from the corresponding author
upon reasonable request. Protein coordinates and structure factors have been deposited
in the RCSB Protein Data Bank under code 6QIG. The source data underlying Figs. 1f,
2a-1, 3a, b and Supplementary Figs. 1a–d are provided as a Source Data ﬁle.
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